Neurodegeneration markers, such as neurofilament light chains and total Tau protein, lack specificity and reflect unspecific neuronal damage from various conditions (e.g., stroke, multiple sclerosis), making them unsuitable to reliably identify AD-related pathology [42]. This evidence concerns the gene MAPT and stroke disorder.